Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer

Neoplasma

Volumn 53, Issue 2, 2006, Pages 119-127

  Vyzula, R ^a   Kocakova I ^a   Demlova R ^a   Kiss, I ^b   Dusek L ^c   Jarkovsky J ^c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c Centre of Biostatistics and Analysis   (Czech Republic)

Author keywords

Colorectal cancer; Oxaliplatin; Palliative chemotherapy; Raltitrexed

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IMMUNOREACTIVE INSULIN; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PARESTHESIA; THROMBOCYTOPENIA; VOMITING;

EID: 33645472791     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. POON MA, O'CONNELL MJ, MOERTEL CG, WIEAND HS, CULLINAN SA et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418.
2. O'CONNELL MJ. A Phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group Study. Cancer 1989; 63 (6 Suppl): 1026-1030.
3. RUSTUM YM, CAO S, ZHANG Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 1998; 4: 12-18.
4. ANON. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
5. PETRELLI N, DOUGLASS HO JR, HERRERA L, RUSSELL D, STABLEIN DM et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-1426.
6. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
7. DE GRAMONT A, BOSSET JF, MILAN C, ROUGIER P, BOUCHE O et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
8. CUNNINGHAM D, ZALCBERG JR, RATH U, OLIVER I, VAN CUTSEM E et al. Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 1996; 7: 961-965.
9. COCCONI G, CUNNINGHAM D, VAN CUTSEM E, FRANCOIS E, GUSTAVSSON B et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943-2952.
10. PAZDUR R, VINCENT M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997; 16: 228a (Abstr 801).
11. COX JV, PAZDUR R, THIBAULT A, MAROUN J, WEAVER C et al. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 265a (Abstr 1016).
12. TWELVES C, HARPER P, VAN CUTSEM E, THIBAULT A, SHELYGIN Y et al. A phase III trial (Sol4796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 263a (Abstr 1010).
13. DIAZ-RUBIO E, SASTRE J, ZANIBONI A, LABIANCA R, CORTES-FUNES H et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9: 105-108.
14. MACHOVER D, DIAZ-RUBIO E, DE GRAMONT A, SCHILF A, GASTIABURU JJ et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
15. BECOUARN Y, ROUGIER P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25 (2 Suppl 5): 23-31.
16. ANDRÉ T, BENSMAINE MA, LOUVET C, FRANCOIS E, LUCAS V et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-3568.
17. LÉVI F, ZIDANI R, MISSET JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-686.
18. LEVI FA, ZIDANI R, VANNETZEL JM, PERPOINT B, FOCAN C et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal metastasis: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-1617.
19. GIACCHETTI S, PERPOINT B, ZIDANI R, LE BAIL N, FAGGIUOLO R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
20. DE GRAMONT A, FIGER A, SEYMOUR M, HOMERIN M, HMISSI A et al. Leucovorin and fluorouracil, with or without oxaliplatin, as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
21. BISMUTH H, ADAM R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25 (2 Suppl 5): 40-46.
22. GIACCHETTI S, ITZHAKI M, GRUIA G, ADAM R, ZIDANI R et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
23. Advanced Colorectal Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
24. CUNNINGHAM D. PYRHÖNEN S, JAMES RD, PUNT CJ, HICKISH TF et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
25. ROUGIER P, VAN CUTSEM E, BAJETTA E, NIEDERLE N, POSSINGER K et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
26. DOUILLARD JY, CUNNINGHAM D, ROTH AD, GERMA JR, JAMES RD et al. A randomized phase III trial comparing irinotecan (IRI)+5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy. Proc Am Soc Clin Oncol 1999; 18: 233a (Abstr 899).
27. VAN CUTSEM E, ROUGIER PH, DROZ JP, MARTY M, H. BLEIBERG H. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5FU. Proc Am Soc Clin Oncol 1997; 16: 268a (Abstr 950).
28. KOCÁKOV́ I, ŠPELDA s, KOCÁK I, BEDNAŘÍK o, KARÁSEK P et al. Weekly irinotecan - effective and well tolerated treatment of metastatic colorectal cancer. Edukační sborník, XXVI. Brněnské onkologické dny 2002; 168 (Abstr 148) in Czech.
29. KARÁSEK P, NÉMEC J, KOCÁKOVÁ I, BEDNAŘÍK O, VŠIANSKÁ M. Irinotecan treatment of advanced colorectal cancer. Česká a slovenská gastroenterologie 1999; 53 (Suppl): 95 (Abstr) in Czech.
30. SALTZ LB, LOCKER PK, PIROTTA N, ELFRING GL, MILLER LL. Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) is superior to daily 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999; 18: 233a (Abstr 898).
31. DOUILLARD JY, CUNNINGHAM D, ROTH AD, GERMA JR, JAMES RD et al. A randomized phase III trial comparing irinotecan plus 5-FU/folinic acid to the same schedule of 5-FU/FA in patients with metastatic colorectal cancer as front-line chemotherapy. Proc Am Soc Clin Oncol 1999; 18: 233a (Abstr 899).
32. SALTZ LB, DOUILLARD J, PIROTTA N, AWAD L, ELFRING G et al. Combined analysis of two phase III randomized trials comparing Irinotecan, fluorouracil (F), Leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2000; 19: 242a (Abstr 938).
33. GAMELIN E, GAMELIN L, DELVA R, GUERIN-MEYER V, MOREL A et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/mg+ chloride infusions: a retrospective study. Proc Am Soc Clin Oncol 2002; 21: 157a (Abstr 624).
34. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
35. StatSoft, Inc. (2004). STATISTICA (data analysis software system), version 6. Available from: URL: http://www.statsoft.com.
36. TOURNIGAND C, ANDRÉ T, ACHILLE E, LLEDO G, FLESH M et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
37. CASCINU S, GRAZIANO F, FERRAU F, CATALANO V, MASSACESI C et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002; 13: 716-720.
38. NERI B, DONI L, FULIGNATI C, PERFETTO K, TURRINI M et al. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. Anticancer Drugs 2002; 13: 719-724.
39. SEITZ JF, BENNOUNA J, PAILLOT B, GAMELIN E, FRANCOIS E et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non pre-treated metastatic colorectal cancer patients. Ann Oncol 2002; 13: 1072-1079.
40. DOUILLARD J, MICHEL P, GAMELIN E, CONROY T, FRANCOIS E et al. Raltitrexed (Tomudex) plus oxaliplatin: An active combination for first-line chemotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 250a (Abstr 971).
41. MARTONI A, MINI E, PINTO C, GENTILE AL, NOBILI S et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res 2003; 23: 687-691.
42. LAUDANI A, GEBBIA V, LEONARDI V, SAVIO G, BORSELLINO N et al. Activity and toxicity of oxaliplatin plus Raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 2004; 24: 1139-1142.
43. VAN CUTSEM E, LAETHEM JL, DIRIX L, HUMBLET Y, VAN EYGEN K et al. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer. Eur J Cancer 2001; 37 (Suppl 6): 273 (Abstr 1008).
44. MURAD A, SCALABRINI NETO AO, CRUZ L. Combination of Raltitrexed and oxaliplatin as a salvage treatment for patients with advanced colorectal cancer refractory to 5-FU based chemotherapy and with hyperexpression of thymidylate synthase. Onkologie 2003; 26 Suppl 3: 34 (Abstr).
45. ALONSO V, VERA R, ALONSO M, ESCUDERO P, ETXEVARRIA A et al. Biweekly Raltitrexed and oxaliplatin in patients with previously treated advanced colorectal carcinoma: Preliminary results. Ann Oncol 2002; 13 Suppl 5: 88 (Abstr).
46. SCHEITHAUER W, KORNEK GV, SCHUELL B, ULRICH-PUR H, PENZ M et al. Second line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based. Ann Oncol 2001; 12: 709-714.